Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT Imaging.
Herein, we present the case of a 49-year-old man with pancreatoblastoma and liver metastasis who underwent preoperative multimodal imaging, in which F-FDG PET/CT showed a markedly increased F-FDG uptake in the metastatic lesion and a slightly increased uptake in the primary lesion.
Evaluation of [<sup>18</sup>F]FDG/[<sup>18</sup>F]FLT/[<sup>18</sup>F]FMISO-based micro-positron emission tomography in detection of liver metastasis in human colorectal cancer.
To assess the feasibility of US-<sup>18</sup>FDG-PET/CT fusion-guided microwave ablation of liver metastases either poorly visible or totally undetectable with US, CEUS and CT, but visualized by PET imaging.
FDG PET/MRI was superior to FDG PET/CT for the detection of local tumour invasion in cervical cancer and had higher accuracy for the detection of liver metastases in colorectal cancer.
To evaluate the feasibility of early metabolic response assessment with <sup>18</sup>F-FDG PET/CT in patients with breast cancer liver metastases 4 weeks after radioembolization with Yttrium-90 labeled microspheres.
TLG response assessment on <sup>18</sup>F-FDG PET/CT appears to be more sensitive and accurate, especially at early follow-up, than size-based response assessment on MR imaging in patients with CRLM treated by RE.
The aim of this study was to determine whether intraprocedural <sup>18</sup>F-FDG PET/CT can be used as a predictor of local tumor progression after percutaneous ablation of colorectal liver metastases.
A staging FDG PET/CT was performed for a 43-year-old woman who was suspected to have splenic malignancy with multiple hepatic metastases revealed on CT images.
The <sup>18</sup>F-FDG PET/CT detected more pulmonary nodules in four patients (one PMCRC in each of these patients) and more extrapulmonary disease in six patients (four mediastinal lymph nodes, one retroperitoneal lymph node and one liver metastases) that the CT-scan had not detected.
The ADCcv index is a potential biomarker of LM with better correlation to <sup>18</sup>F-FDG PET SUVpeak than conventional MRI metrics, and may serve to quantitatively discriminate between LM and NAL.
Imaging with F-FDG PET showed low glucose avidity in disease sites but Ga-PSMA PET unequivocally demonstrated multiple skeletal and liver metastases with intense PSMA avidity.
Apart from showing increased FDG uptake in the primary site and locoregional nodal and liver metastases, an unusual site of intense FDG focus was demonstrated in the left adrenal gland.